Embecta (EMBC) Competitors

LeMaitre Vascular (NASDAQ:LMAT) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Which has stronger earnings & valuation, LMAT or EMBC?

Embecta has higher revenue and earnings than LeMaitre Vascular. Embecta is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$219.86M	9.32	$30.10M	$1.94	46.77
Embecta	$1.11B	0.64	$78.30M	$1.00	12.19

Is LMAT or EMBC more profitable?

LeMaitre Vascular has a net margin of 19.40% compared to Embecta's net margin of 5.25%. LeMaitre Vascular's return on equity of 13.15% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	19.40%	13.15%	11.47%
Embecta	5.25%	-19.22%	11.92%

Is LMAT or EMBC a better dividend stock?

LeMaitre Vascular pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 4.9%. LeMaitre Vascular pays out 41.2% of its earnings in the form of a dividend. Embecta pays out 60.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. LeMaitre Vascular has raised its dividend for 14 consecutive years.

Does the media favor LMAT or EMBC?

In the previous week, LeMaitre Vascular had 6 more articles in the media than Embecta. MarketBeat recorded 11 mentions for LeMaitre Vascular and 5 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat LeMaitre Vascular's score of 1.17 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, LMAT or EMBC?

LeMaitre Vascular has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Does the MarketBeat Community favor LMAT or EMBC?

LeMaitre Vascular received 514 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 70.45% of users gave LeMaitre Vascular an outperform vote while only 5.56% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
LeMaitre Vascular	Outperform Votes 515 70.45%	Underperform Votes 216 29.55%
Embecta	Outperform Votes 1 5.56%	Underperform Votes 17 94.44%

Do institutionals & insiders believe in LMAT or EMBC?

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by company insiders. Comparatively, 0.4% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend LMAT or EMBC?

LeMaitre Vascular currently has a consensus price target of $98.14, suggesting a potential upside of 8.16%. Embecta has a consensus price target of $20.33, suggesting a potential upside of 66.80%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

LeMaitre Vascular beats Embecta on 14 of the 22 factors compared between the two stocks.